FATE Form 4: CFO awarded RSUs, 375,000 options expiring 10/20/2035

Q: What did Fate Therapeutics (FATE) disclose in this Form 4?

The CFO was granted 75,000 RSUs and a stock option for 375,000 shares on 10/20/2025 .

Q: How do the 75,000 RSUs for FATE’s CFO vest?

The RSUs vest 25% on Nov 1, 2026 , Nov 1, 2027 , Nov 1, 2028 , and Nov 1, 2029 , subject to continued service.

Q: What are the key terms of the 375,000 stock options?

The option has a $1.54 exercise price, vests 25% on Oct 20, 2026 then monthly over 36 months, and expires on Oct 20, 2035 .

Q: How many securities does the CFO beneficially own after these awards?

75,000 shares of common stock and 375,000 stock options, as reported.

Q: Who is the reporting person in this FATE filing?

The company’s Chief Financial Officer is the reporting person.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Fate Therapeutics (FATE) reported a Form 4 showing its Chief Financial Officer received equity awards on 10/20/2025. The CFO was granted 75,000 restricted stock units at $0.00, which vest 25% on November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029. The CFO also received a stock option for 375,000 shares at an exercise price of $1.54, vesting 25% on October 20, 2026 and monthly thereafter for 36 months, expiring on October 20, 2035. Following the transactions, the filing lists 75,000 common shares and 375,000 options beneficially owned.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Adawi Kamal

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	375,000	$0.00	--
Grant/Award	Common Stock	75,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 375,000 shares (Direct); Common Stock — 75,000 shares (Direct)

Footnotes (1)

Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. The option shall vest as to 25% of the underlying shares on October 20, 2026 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

10/21/2025 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adawi Kamal

(Last)

(First)

(Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO

92131

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/20/2025		A⁽¹⁾		75,000	A	$0.00	75,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.54	10/20/2025		A		375,000		⁽²⁾	10/20/2035	Common Stock	375,000	$0	375,000	D

Explanation of Responses:

1. Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

2. The option shall vest as to 25% of the underlying shares on October 20, 2026 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

	/s/ Cindy Tahl, as Attorney-in-Fact	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Fate Therapeutics (FATE) disclose in this Form 4?

The CFO was granted 75,000 RSUs and a stock option for 375,000 shares on 10/20/2025.

How do the 75,000 RSUs for FATE’s CFO vest?

The RSUs vest 25% on Nov 1, 2026, Nov 1, 2027, Nov 1, 2028, and Nov 1, 2029, subject to continued service.

What are the key terms of the 375,000 stock options?

The option has a $1.54 exercise price, vests 25% on Oct 20, 2026 then monthly over 36 months, and expires on Oct 20, 2035.

How many securities does the CFO beneficially own after these awards?

75,000 shares of common stock and 375,000 stock options, as reported.

Who is the reporting person in this FATE filing?

The company’s Chief Financial Officer is the reporting person.

What is the transaction date for these equity awards?

October 20, 2025.